Xu B, Li H, Zhang Q, Sun W, et al. Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women. Cancer Chemother Pharmacol 2021 Apr 9. pii: 10.1007/s00280-021-04263.
PMID: 33835229